首页 | 本学科首页   官方微博 | 高级检索  
     

125I粒子近距离治疗在局部晚期腮腺腺样囊性癌的应用
引用本文:高雅,张杰,刘树铭,郑磊,黄明伟,张建国. 125I粒子近距离治疗在局部晚期腮腺腺样囊性癌的应用[J]. 中华放射医学与防护杂志, 2021, 41(1): 9-13
作者姓名:高雅  张杰  刘树铭  郑磊  黄明伟  张建国
作者单位:北京大学口腔医学院·口腔医院口腔颌面外科 国家口腔疾病临床医学研究中心 口腔数字化医疗技术和材料国家工程实验室 口腔数字医学北京市重点实验室 100081
摘    要:目的单纯应用125I放射性粒子组织间植入治疗局部晚期腮腺腺样囊性癌,评估疗效并分析相关预后因素,为局部晚期腮腺腺样囊性癌的治疗提供临床参考。方法回顾性纳入2007年8月至2018年1月于北京大学口腔医院接受单纯应用125I放射性粒子植入治疗的局部晚期腮腺腺样囊性癌患者,分析其总生存率(OS)、无进展生存率(PFS)和局部控制率(LCR)及相关影响因素,并观察近、远期放射不良反应情况。结果本组病例共16例(cT4bN0M0),女性患者占多数(11/16,68.7%),中位年龄55.4岁。随访8~104个月(中位时间41.5个月),1、3、5年LCR分别为93.7%、80%、68.7%,1、3、5年OS分别为86.7%、72%、54%;1、3、5年PFS分别为74%、53%、18.9%。9例(56.2%)患者出现不同部位器官转移,以颅内转移、肺转移常见;其中6例术前伴有颅底骨质侵犯者出现多器官转移,肿瘤侵犯颈动脉是影响远处转移的危险因素(HR=12,P=0.045)。共有8例(8/16,50%)患者出现不同程度远期放射性不良反应。结论单纯应用125I放射性粒子植入治疗局部晚期腮腺腺样囊性癌的5年局部控制率为68.7%,肿瘤侵犯颅底骨质、包绕颈动脉是其预后不佳与发生多器官远处转移的主要因素。

关 键 词:腮腺  腺样囊性癌  125I放射性粒子  近距离治疗  局部晚期
收稿时间:2020-05-25
修稿时间:2020-05-25

Application of 125I interstitial brachytherapy in the treatment of local advanced parotid adenoid cystic carcinoma
Gao Y,Zhang Jie,Liu Shuming,Zheng Lei,Huang Mingwei,Zhang Jianguo. Application of 125I interstitial brachytherapy in the treatment of local advanced parotid adenoid cystic carcinoma[J]. Chinese Journal of Radiological Medicine and Protection, 2021, 41(1): 9-13
Authors:Gao Y  Zhang Jie  Liu Shuming  Zheng Lei  Huang Mingwei  Zhang Jianguo
Affiliation:Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Peking University, National Clinical Research Center for Oral Diseases, National Engineering Laboratory of Dental Digital Medical Technology and Materials, Beijing Key Laboratory of Dental Digital Medicine, Beijing 100081, China
Abstract:Objective To evaluate the efficacy of 125I interstitial brachytherapy in the treatment of local advanced parotid adenoid cystic carcinoma (ACC), and to analyze prognostic factors affecting treatment outcome, in order to provide references for the treatment of local advanced parotid adenoid cystic carcinoma.Methods Patients with histology-confirmed ACC of the parotid who received 125I interstitial brachytherapy in Peking University Hospital of Stomatology between Aug 2007 and Jan 2018 were included.Prognostic factors affecting overall survival (OS), progression-free survival (PFS), and local control rate (LCR) were analyzed.Meanwhile, distant metastases as well as acute and long-term radiological toxicities were described.Results A total of 16 patients (11 females, mean age 55.4 years) of stage cT4bN0M0 who received definitive 125I interstitial brachytherapy were included.The median follow-up period was 41.5 months (8-104 months),and the 1-, 3- and 5-year OS were 86.7%, 72% and 54%, respectively.Five patients suffered from local recurrence, the 1-, 3- and 5-year LCR were 93.7%, 80% and 68.7%, respectively, and the 1-, 3- and 5-year PFS were 74%, 53%, and 18.9%, respectively.Nine cases developed distant metastases.Among them, intracranial and pulmonary metastases took place the most frequently and six patients who had skull base invasion developed multi-organ metastases.An encased carotid artery was an independent prognostic factor for distant metastases (HR=12, P=0.045). Severe radiological toxicities were observed in eight patients (8/16, 50%), including radio-dermatitis, hearing loss, progressive trismus, and eye toxicities.Conclusions The 5-year LCR in patients treated with definitive 125I interstitial brachytherapy for local advanced ACC of the parotid was 68.7%, and skull base invasion and an encased carotid artery were independent adverse prognostic factors of bad prognosis and multi-organ metastases.
Keywords:Parotid  Adenoid cystic carcinoma  125I radioactive seeds  Interstitial brachytherapy  Local advanced stage
本文献已被 维普 等数据库收录!
点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息
点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号